Skip to Main Content

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, everyone. Damian here with a look at a pioneering new gene therapy, the plight of WuXi AppTec, and a rough month for biotech’s neuroscience renaissance.

advertisement

The need-to-know this morning

  • AstraZeneca said it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.
  • Crinetics Pharmaceuticals said its experimental drug called paltusotine achieved the goals of a Phase 3 study in patients with acromegaly, a rare endocrine disorder. Crinetics intends to submit a marketing application to the FDA in the second half of the year.
  • PureTech Health proposed a return of $100 million to its shareholders by way of a tender offer of its shares. PureTech made nearly $300 million from its remaining stake in Karuna Therapeutics, which was acquired by Bristol Myers Squibb.
  • Madrigal Pharmaceuticals raised $600 million in a follow-on stock offering, following last week’s approval of its drug to treat the liver disease known as MASH.

FDA approves a pioneering gene therapy

Orchard Therapeutics yesterday won U.S. approval for a gene therapy that, when given early in patients’ lives, can nearly cure a devastating inherited disorder that eats away at children’s neurons.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

To submit a correction request, please visit our Contact Us page.